Skip to main content

Amantadine Hydrochloride (Antiviral) (Monograph)

Drug class: Adamantanes

Medically reviewed by Drugs.com on May 10, 2024. Written by ASHP.

Introduction

Adamantane derivative; synthetic antiviral agent that is active against influenza A virus.1 2 6

Uses for Amantadine Hydrochloride (Antiviral)

Treatment of Seasonal Influenza A Virus Infections

Has been used for treatment of uncomplicated respiratory tract illness caused by various strains of influenza A virus in adults, adolescents, and children ≥1 year of age.1 2 6 16 19 24 26 27 34 41 60 74 75

Amantadine is not a substitute for vaccination as recommended by CDC.1 2 6

Neuraminidase inhibitors (e.g., oseltamivir, zanamivir, peramavir) are currently recommended if antiviral treatment is needed in patients with suspected or confirmed influenza; adamantanes (amantadine, rimantadine) are no longer recommended for such use because of high levels of resistance among circulating influenza A viruses.137 138

Consider viral surveillance data from local and state health departments and CDC when selecting an antiviral for treatment of seasonal influenza.112 137 488 Strains of circulating influenza viruses and the antiviral susceptibility of these strains constantly evolve.112 137 144

CDC issues recommendations concerning the use of antiviral agents for the treatment of influenza, and these recommendations are updated as needed during each influenza season.137 144 Information regarding influenza surveillance and updated recommendations for treatment of seasonal influenza are available from CDC at [Web]

Prevention of Seasonal Influenza A Virus Infections

Has been used for prophylaxis against influenza infection caused by susceptible influenza A viruses in adults, adolescents, and children ≥1 year of age.1 2 6 22 24 27 34 42 44 45 46 73 71 72

Annual vaccination with seasonal influenza virus vaccine, as recommended by CDC, is the primary means of preventing seasonal influenza and severe complications; amantadine is not a substitute for early vaccination.1 2 6 105 112 116 144 488

The Infectious Diseases Society of America (IDSA) states that antiviral drugs should not be used for routine or widespread chemoprophylaxis outside of institutional outbreaks, but may be considered in certain situations (e.g., patients at high risk of developing complications from influenza).138 If antiviral chemoprophylaxis is needed, neuraminidase inhibitors are recommended; adamantanes (amantadine, rimantadine) should not be used for chemoprophylaxis because of high levels of resistance among circulating influenza A viruses.137 138

Consider viral surveillance data available from local and state health departments and the CDC when selecting an antiviral for prophylaxis of influenza.112 137 488 The most appropriate antiviral for prevention of influenza is selected based on information regarding the likelihood of the influenza strain being susceptible and the known adverse effects of the drug.137 144

CDC issues recommendations concerning the use of antiviral agents for prophylaxis of influenza, and these recommendations are updated as needed during each influenza season.137 144 Information regarding influenza surveillance and updated recommendations for prevention of seasonal influenza are available from CDC at [Web]

Amantadine Hydrochloride (Antiviral) Dosage and Administration

General

Patient Monitoring

Administration

Administer orally.1 2 6 Adverse effects (e.g., CNS effects) may be minimized if the daily dosage is given in 2 equally divided doses.1 2 6

Commercially available as tablets or liquid-filled capsules containing 100 mg of amantadine hydrochloride and as an oral solution containing 50 mg/5 mL of the drug.1 2 6

Dosage

Pediatric Patients

Treatment of Seasonal Influenza A Virus Infections
Oral

Children 1–9 years of age: Manufacturers recommend 4.4–8.8 mg/kg (up to 150 mg) daily.1 2 6 AAP recommends 5 mg/kg (up to 150 mg) daily in 2 divided doses.105

Children 9–12 years of age: Manufacturers recommend 100 mg twice daily.1 2 6

Children ≥10 years of age: AAP recommends 5 mg/kg daily in 2 divided doses in those weighing <40 kg or 100 mg twice daily in those weighing ≥40 kg.105

Initiate as soon as possible, preferably within 24–48 hours after onset of symptoms, and continue for 24–48 hours after symptoms disappear.1 2 6

Prevention of Seasonal Influenza A Virus Infections
Oral

Children 1–9 years of age: Manufacturer recommends 4.4–8.8 mg/kg (up to 150 mg) daily.1 2 6 AAP recommends 5 mg/kg (up to 150 mg) daily in 2 divided doses.105

Children 9–12 years of age: Manufacturer recommends 100 mg twice daily.1 2 6

Children ≥10 years of age: AAP recommends 5 mg/kg daily in 2 divided doses in those weighing <40 kg or 100 mg twice daily in those weighing ≥40 kg.105

While the manufacturers state that a dosage of 100 mg once daily has not been evaluated in children,1 2 6 AAP suggests that a dosage of 100 mg daily is an acceptable alternative dosage for prophylaxis of influenza A illness in children weighing >20 kg.105

Continue prophylaxis for at least 10 days following a known exposure.1 2 6 If used as adjunct to influenza vaccination, continue for 2–4 weeks after vaccine is given to provide prophylaxis until protective antibody response develops.1 2 6

Adults

Treatment of Seasonal Influenza A Virus Infections
Oral

200 mg once daily or 100 mg twice daily.1 2 6

Dosage may be decreased to 100 mg daily in those who experience CNS or other toxicities with 200 mg daily; relative efficacy of lower dosage not elucidated.1 2 6

Initiate as soon as possible, preferably within 24–48 hours after onset of symptoms, and continue for 24–48 hours after symptoms disappear.1 2 6

Prevention of Seasonal Influenza A Virus Infections
Oral

200 mg once daily or 100 mg twice daily.1 2 6

Dosage may be decreased to 100 mg daily in those who experience CNS or other toxicities with 200 mg daily; relative efficacy of lower dosage not elucidated.1 2 6

Continue prophylaxis for at least 10 days following a known exposure.1 2 6 If used as adjunct to influenza vaccination, continue for 2–4 weeks after vaccine is given to provide prophylaxis until protective antibody response develops.1 2 6

Special Populations

Hepatic Impairment

Manufacturers make no dosage adjustment recommendations for patients with hepatic impairment.1 2 6

Renal Impairment

Patients with Clcr 30–50 mL/minute per 1.73 m2 should receive 200 mg the first day, followed by 100 mg once daily thereafter.1 2 6

Patients with Clcr15–29 mL/minute per 1.73 m2 should receive 200 mg the first day, followed by 100 mg on alternate days thereafter.1 2 6

Patients with Clcr <15 mL/minute per 1.73 m2 and hemodialysis patients should receive 200 mg every 7 days.1 2 6

Geriatric Patients

Usual dosage in adults ≥65 years of age without recognized renal disease is 100 mg once daily.1 2 6

Some clinicians state that 100 mg daily should be the maximum dosage for adults ≥65 years of age, and that dosage may need to be further reduced in some geriatric patients.1 2 6

Cautions for Amantadine Hydrochloride (Antiviral)

Contraindications

Warnings/Precautions

Deaths from Overdosage

Deaths from overdosage have occurred.1 2 6 Acute toxicity may be attributed to the anticholinergic effects of the drug.1 2 6

Overdosage also reported in patients with renal impairment who were prescribed higher than recommended doses.1 2 6

Suicidality and Depression

Suicide attempts (sometimes resulting in death) and suicidal ideation reported; in many cases, patients received short courses of the drug for influenza prophylaxis or treatment.1 2 6

Monitor patients for depression, including suicidal ideation and behavior.1 2 6

Weigh risks versus benefits of treatment in patients with a history of suicidality or depression.1 2 6

Hallucinations and Psychotic Behavior

Hallucinations and other psychiatric symptoms (e.g., confusion, psychosis, personality changes, agitation, aggressive behavior, paranoia) reported.1 2 6

Monitor patients for these effects, particularly after initiation of therapy and when dosage is increased or decreased.1 2 6

Use of amantadine generally not advised in patients with major psychotic disorders because of risk of exacerbating psychosis.1 2 6

CNS Effects

Possible increased seizure frequency in patients with active seizure disorders.1 2 6 Seizures also reported in patients with renal impairment and in geriatric individuals.1 2 6

Observe patients with a history of seizures closely for possible increased seizure activity.1 2 6

May impair ability to perform hazardous activities requiring mental alertness or physical coordination such as operating machinery or driving a motor vehicle.1 2 6

Dizziness and Orthostatic Hypotension

Dizziness and orthostatic hypotension reported.1 2 6

Monitor patients for signs and symptoms of orthostatic hypotension, particularly after initiation of therapy and when dosage is increased.1 2 6

Neuroleptic Malignant Syndrome

A symptom complex resembling possible neuroleptic malignant syndrome (NMS; characterized by fever, muscular rigidity, altered consciousness, autonomic instability) reported with drugs that increase central dopaminergic tone; observed with rapid dosage reduction or withdrawal of drug.1 2 6

Observe patients carefully when dosage is reduced abruptly or treatment is discontinued.1 2 6

Impulse Control and Compulsive Behaviors

Intense urges (e.g., urge to gamble, increased sexual urges, binge eating, uncontrolled spending, other intense urges) and inability to control these urges reported with medications that increase central dopaminergic tone.1 2 6

Consider reducing dosage or discontinuing therapy if a patient develops such urges.1 2 6

Melanoma

Melanoma observed more frequently in patients with parkinson disease than in the general population.1 2 6

Monitor for melanoma on a frequent and regular basis.1 2 6 Periodic dermatologic screening is recommended by some manufacturers.1 2 6

Specific Populations

Pregnancy

No adequate data in pregnant women; in animal studies, adverse developmental effects (e.g., embryolethality, malformations, reduced fetal body weight) observed.1 2 6

Lactation

Do not use in nursing women; distributed into human milk.1 2 6

Pediatric Use

Safety and efficacy for the prevention or treatment of infections caused by influenza A viruses not established in neonates or children <1 year of age.1 2 6

Geriatric Use

Substantially eliminated by the kidneys.1 2 6 Consider age-related decreases in renal function and the potential for concomitant disease when selecting dosage.1 2 6

Hepatic Impairment

Use with caution in patients with liver disease; increased concentrations of liver enzymes reported.1 2 6

Renal Impairment

Mainly excreted in the urine; drug accumulation may occur when renal function declines. Reduced dosages recommended in patients with renal impairment.1 2 6

Common Adverse Effects

Most common adverse effects (5–10%): nausea, dizziness, insomnia.1 2 6

Drug Interactions

Specific Drugs

Drug

Interaction

Comments

Alcohol

Potential for increased risk of CNS effects1 2 6

Concomitant use not recommended1 2 6

Anticholinergic agents

Potential for increased adverse anticholinergic and CNS effects1 2 6 90 91 92 93

Dosage adjustment of both drugs may be needed1 2 6 90 91 92 93

CNS stimulants

Possible additive CNS stimulant effects1 2 6

Administer amantadine with caution in patients receiving other CNS stimulant drugs1 2 6

Co-trimoxazole

Toxic delirium has occurred following initiation of co-trimoxazole in at least one patient who had been stabilized on amantadine98

Influenza virus vaccine

Influenza virus vaccine inactivated: Amantadine does not interfere with the antibody response to the vaccine1 2 6

Influenza vaccine live intranasal: Potential interference with antibody response to the live vaccine; no specific studies1 2 6 100

Influenza virus vaccine inactivated: May be administered concomitantly with or at any interval before or after amantadine1 2 6 100

Influenza vaccine live intranasal: Do not administer the live vaccine until ≥48 hours after amantadine is discontinued; do not administer amantadine until ≥2 weeks after administration of the vaccine, unless medically indicated;1 2 6 100 if amantadine given within 2 weeks after the vaccine, repeat vaccine dose ≥48 hours after last antiviral dose;100 alternatively, if amantadine given 2 days before to 14 days after the vaccine, revaccinate using the parenteral inactivated vaccine or parenteral recombinant vaccine100

Quinidine or quinine

May reduce the renal clearance of amantadine1 2 6

Triamterene and hydrochlorothiazide

Increased plasma concentrations of amantadine reported; however, not known which component of the combination preparation may have been responsible for the interaction1 2 6

Amantadine Hydrochloride (Antiviral) Pharmacokinetics

Absorption

Bioavailability

Well absorbed from the GI tract.1 2 6 12 27 45 56 63 67

Elimination

Elimination Route

Principally excreted unchanged in urine by glomerular filtration and tubular secretion; at least 8 metabolites have been identified in urine.1 2 6 19 48 67

Not appreciably removed by dialysis.1 2 6 8 9 67

Half-life

9–37 hours, with an average of 24 hours or less.1 2 6 48 56 63 65 67 68

Stability

Storage

Oral

Capsules, Tablets, and Oral Solution

20–25°C (excursions permitted between 15–30°C; dispense in tight, light-resistant container.1 2 6

Actions

Advice to Patients

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Amantadine Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

100 mg*

Amantadine Hydrochloride Capsules

Solution

50 mg/5 mL*

Amantadine Hydrochloride Solution

Tablets

100 mg*

Amantadine Hydrochloride Tablets

AHFS DI Essentials™. © Copyright 2024, Selected Revisions May 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Upsher-Smith Laboratories. Amantadine hydrochloride tablets prescribing information. Minneapolis, MN; 2023 May.

2. Chartwell RX. Amantadine hydrochloride oral solution prescribing information. Congers, NY; 2023 Jan.

6. Upsher-Smith. Amantadine hydrochloride capsules prescribing information. Maple Grove, MN; 2023 May.

8. Soung LS, Ing TS, Daugirdas JT et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Ann Intern Med. 1980; 93(1 Part 1):46-9. http://www.ncbi.nlm.nih.gov/pubmed/7396313?dopt=AbstractPlus

9. Horadam VW, Sharp JG, Smilack JD et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981; 94(4 Part 1):454-8. http://www.ncbi.nlm.nih.gov/pubmed/7212501?dopt=AbstractPlus

12. Hayden FG, Minocha A, Spyker DA et al. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother. 1985; 28:216-21. http://www.ncbi.nlm.nih.gov/pubmed/3834831?dopt=AbstractPlus

16. Douglas RG Jr. Treatment of influenza. N Engl J Med. 1990; 322:1753.

19. Van Voris LP, Betts RF, Hayden FG et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981; 245:1128-31. http://www.ncbi.nlm.nih.gov/pubmed/7007668?dopt=AbstractPlus

22. Hayden FG, Belshe RB, Clover RD et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989; 321:1696-702. http://www.ncbi.nlm.nih.gov/pubmed/2687687?dopt=AbstractPlus

24. Douglas RG Jr. Prophylaxis and treatment of influenza. N Engl J Med. 1990; 322:443-50. http://www.ncbi.nlm.nih.gov/pubmed/2405270?dopt=AbstractPlus

26. Hayden FG. Antiviral agents: other antiviral agents. In: Hardman JG, Goodman LS, Gillman A et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:1209-11.

27. Anon. Amantadine (Symmetrel) and rimantadine (Flumadine). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995:417-9.

29. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis. 1992; 15:362-7. http://www.ncbi.nlm.nih.gov/pubmed/1520770?dopt=AbstractPlus

34. Dolin R, Reichman RC, Madore HP et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982; 307:580-4. http://www.ncbi.nlm.nih.gov/pubmed/7050702?dopt=AbstractPlus

41. Wingfield WL et al. Therapeutic efficacy of amantadine hydrochloride and rimantadine hydrochloride in naturally occurring influenza A2 respiratory illness in man. N Engl J Med. 1969; 281:579-84. http://www.ncbi.nlm.nih.gov/pubmed/4897137?dopt=AbstractPlus

42. Hayden FG. Antivirals for pandemic influenza. J Infect Dis. 1997; 176(Suppl 1):S56-61.

44. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother. 1995; 29:299-310. http://www.ncbi.nlm.nih.gov/pubmed/7606077?dopt=AbstractPlus

45. Anon. Amantadine and rimantadine. In: Kucers A, Crowe SM, Grayson ML et al, eds. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Boston, MA: Butterworth-Heinemann; 1997:1834-54.

46. Kimberlin DW, Whitley RJ. Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother. 1996; 37:403-21. http://www.ncbi.nlm.nih.gov/pubmed/9182098?dopt=AbstractPlus

47. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol. 1992; 3:21-30.

48. Tilley JW, Kramer MJ. Aminoadamantane derivatives. Prog Med Chem. 1981; 18:1-44. http://www.ncbi.nlm.nih.gov/pubmed/7045980?dopt=AbstractPlus

49. Hayden FG, Gwaltney JM Jr, Van de Castle RL et al. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother. 1981; 19:226-33. http://www.ncbi.nlm.nih.gov/pubmed/7347558?dopt=AbstractPlus

50. US Centers for Disease Control and Prevention. Information on avian influenza. From CDC website. Accessed 2014 Feb 4. http://www.cdc.gov/flu/avianflu/index.htm

52. World Health Organization. WHO guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. Revised February 2010. Part I. Recommendations. From WHO website. Accessed 3 Oct 2010. https://www.ncbi.nlm.nih.gov/books/NBK138515/

56. Bleidner WE et al. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965; 150:1-7. http://www.ncbi.nlm.nih.gov/pubmed/5322550?dopt=AbstractPlus

60. Little JW et al. Amantadine effect on peripheral airway abnormalities in influenza. Ann Intern Med. 1976; 85:177-82. http://www.ncbi.nlm.nih.gov/pubmed/782310?dopt=AbstractPlus

63. Rizzo M et al. Amantadine in depression: relationship between behavioral effects and plasma levels. Eur J Clin Pharmacol. 1973; 5:226-8.

65. Fahn S et al. Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol. 1971; 25:45-8. http://www.ncbi.nlm.nih.gov/pubmed/5146411?dopt=AbstractPlus

67. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988; 14:35-51. http://www.ncbi.nlm.nih.gov/pubmed/3280212?dopt=AbstractPlus

68. Montanari C et al. Urinary excretion of amantadine by the elderly. Eur J Clin Pharmacol. 1975; 8:349-51. http://www.ncbi.nlm.nih.gov/pubmed/1233234?dopt=AbstractPlus

71. Smordintsev AA et al. Evaluation of amantadine in artificially induced A2 and B influenza. JAMA. 1970; 213:1448-54. http://www.ncbi.nlm.nih.gov/pubmed/4915518?dopt=AbstractPlus

72. Oker-Blom N et al. Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled study. Br Med J. 1970; 3:676-8. http://www.ncbi.nlm.nih.gov/pubmed/4919024?dopt=AbstractPlus

73. Monto AS, Ohmit SE, Hornbuckle K et al. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother. 1995; 39:2224-8. http://www.ncbi.nlm.nih.gov/pubmed/8619572?dopt=AbstractPlus

74. Galbraith AW et al. Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A2/Hong Kong infection. Lancet. 1971; 2:13-5.

75. Knight V et al. Amantadine therapy of epidemic influenza A2/Hong Kong. Antimicrob Agents Chemother. 1969:370-1.

90. insert title. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:411.

91. Schwab RS et al. Amantadine in Parkinson's disease. JAMA. 1972; 222:792-5. http://www.ncbi.nlm.nih.gov/pubmed/4677928?dopt=AbstractPlus

92. Schwab RS, England AC. Amantadine HCl (Symmetrel) and its relation to levodopa in the treatment of Parkinson's disease. Trans Am Neurol Assoc. 1969; 94:85-90. http://www.ncbi.nlm.nih.gov/pubmed/4907453?dopt=AbstractPlus

93. Voeller GW. German study: role of Symmetreleg; in drug treatment. In: Birdwood GFB et al, eds. Parkinson's disease. A new approach to treatment. Academic Press. New York; 1971:49-53.

98. Speeg KV, Leighton JA, Maldonado AL. Case report: toxic delirium in a patient taking amantadine and trimethoprim-sulfamethoxazole. Am J Med Sci. 1989; 298:410-2. http://www.ncbi.nlm.nih.gov/pubmed/2596498?dopt=AbstractPlus

100. Influenza Division, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2013; 62(RR-07):1-43.

105. American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.

112. Committee on Infectious Disease. Recommendations for Prevention and Control of Influenza in Children, 2013–2014. Pediatrics. 2013; :.

116. Harper SA, Bradley JS, Englund JA et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:1003-32. http://www.ncbi.nlm.nih.gov/pubmed/19281331?dopt=AbstractPlus

117. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2010; 59:423-30. http://www.ncbi.nlm.nih.gov/pubmed/20395936?dopt=AbstractPlus

121. Centers for Disease Control and Prevention. High level of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents—United States, 2005–06 influenza season. MMWR Morb Mortal Wkly Rep. 2006; 55:44-6. http://www.ncbi.nlm.nih.gov/pubmed/16424859?dopt=AbstractPlus

127. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-8):1-40. http://www.cdc.gov/mmwr/PDF/rr/rr5408.pdf

137. Centers for Disease Control and Prevention. For clinicians: antiviral medication. From CDC website. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

138. Uyeki TM, Bernstein HH, Bradley JS et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902. doi: 10.1093/cid/ciy874. PMID: 30834445; PMCID: PMC6769232.

144. Fiore AE, Fry A, Shay D et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60:1-24. http://www.ncbi.nlm.nih.gov/pubmed/21248682?dopt=AbstractPlus

162. . Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly Epidemiol Rec. 2010; 85:81-92. http://www.ncbi.nlm.nih.gov/pubmed/20210260?dopt=AbstractPlus

488. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 12th ed. Washington DC: Public Health Foundation; 2012 May. Updates may be available at CDC website. http://www.cdc.gov/vaccines/pubs/pinkbook/flu.html

551. Centers for Disease Control and Prevention (CDC). Influenza activity--United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2013; 62:473-9. http://www.ncbi.nlm.nih.gov/pubmed/23760189?dopt=AbstractPlus

552. . Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season. Wkly Epidemiol Rec. 2013; 88:101-14. http://www.ncbi.nlm.nih.gov/pubmed/23544236?dopt=AbstractPlus

Frequently asked questions

View more FAQ